Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning

Quest Diagnostics Incorporated (NYSE: DGX ) stock surged Thursday after the diagnostic testing company reported second-quarter results that topped Wall Street expectations and raised its full-year 2026 guidance. 83. 973 billion consensus estimate. Consolidated organic revenue grew 10%.

8% to $502 million. Quest Diagnostics’ second-quarter results showed growth across every major customer channel, with strong demand from physicians, hospitals and consumers driving a 10% increase in organic revenue. Management also highlighted robust momentum in preventive healthcare, saying its consumer wellness business continued to expand as more people sought health screening and diagnostic tests, reinforcing the company’s long-term growth strategy.

1% from a year earlier, while organic volume rose 13%, driven by broad clinical demand from physicians, hospitals and consumers, as well as higher testing volumes from collaborations with Corewell Health and Fresenius Medical Care. The Corewell Health and Fresenius relationships contributed about 9% of total volume during the quarter. 1%. 8% year over year, reflecting the business mix from the two partnerships.

9%, primarily due to a higher number of tests per requisition. Unit price reimbursement was flat from a year earlier, in line with company expectations. Quest Diagnostics Raises Full-Year Outlook “With strong growth and sustained demand for our diagnostic insights, we are again raising our full-year guidance,” Chairman, President and CEO Jim Davis said. 76.

90 billion. 851 billion. 71 at the time of publication on Thursday. The stock is trading at a new 52-week high, according to Pro data.

Image via Shutterstock Read Also: Tesla Could 'Eventually Drop a Bomb on Waymo,' Gene Munster Says, After AI Chief Signals Statewide Robotaxi Launches